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ORIGINAL ARTICLE

Comparison of the Effects of a Pharmaceutical
Industry Decision Guide and Decision Aids
on Patient Choice to Intensify Therapy
in Rheumatoid Arthritis
Richard W. Martin, MD, MA, Ryan D. Enck, MD, Donald J. Tellinghuisen, PhD,
Aaron T. Eggebeen, MD, James D. Birmingham, MD, Andrew J. Head, MD

Objective. To compare the effects a pharmaceutical
industry decision guide and International Patient
Decision Aids Standard (IPDAS) compliant patient decision aids (PtDA) on patient medication beliefs and
choice to intensify therapy. Methods. Rheumatoid arthritis (RA) patients, who had never taken etanercept
(Enbrel), took part in a mail survey. They were presented
with a hypothetical decision scenario where they were
asked to consider adding etanercept to their current regimen. Each patient was randomized to review 1 of 3
forms of an etanercept-specific decision support: a long
PtDA (LONG DA), a short PtDA (SHORT DA), or the
manufacturer’s Enbrel decision guide (Pharm Booklet).
Results. We had 402 RA patients participate in the study
(response rate, 52%). Of the patients randomized to the
Pharm Booklet, 30.6% elected to initiate etanercept.
Only 14.6% and 14.0% of patients who reviewed the
LONG DA or SHORT DA choose to take etanercept (x2 =
15.7; P \ 0.001). Patients who reviewed the LONG DA or
SHORT DA had a greater increase in knowledge about
etanercept than those who reviewed the Pharm Booklet.
There was no difference in decisional conflict among the

groups. A logistic regression model explained 44.2%
(R2 = 0.442) of patient choice to intensify therapy by
initiating etanercept. The strongest predictor of choice to
intensify therapy were beliefs about etanercept’s ability
to improve symptoms (OR = 2.56, 96%CI [1.71, 3.80]),
and its use by others like the respondent (OR = 2.24,
95%CI [1.49, 3.35]). Mediation analysis confirmed the
presence of a partial mediating effect of decision support
on patients’ intent to take etanercept (OR = 0.59,
95%CI [0.39, 0.89]). Conclusions. Patients supported by
the Pharm Booklet were twice as likely to choose to intensify therapy. The Pharm Booklet’s effects are partially
mediated through persuasive communication techniques
that influence patients’ beliefs that symptoms will improve,
and increase social normative beliefs, rather than by
increasing the relevant knowledge, clarifying patient values
about positive or negative treatment outcomes, or increasing their self-efficacy. Key words: decision making;
patient decision aid; evaluative conditioning; beliefs
about medications; etanercept; disease-modifying antirheumatic drugs; rheumatoid arthritis; causal mediation.
(Med Decis Making 2017;37:577–588)

P

have a limited ability to comprehend complex riskbenefit information.3,4
Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes joint pain, functional impairment and irreversible joint damage. Etanercept is
an injectable protein that targets and blocks the
pro-inflammatory cytokine tumor necrosis factor-a
(TNFa). Etanercept is utilized as a disease modifying
anti-rheumatic drug (DMARD), which reduces joint
swelling and pain as well as slows the development
of joint damage.5,6
When physicians propose a new high-risk medication, like etanercept for RA, it is common practice

hysicians are morally and legally obligated to
obtain informed consent when initiating medical
therapies. It should be expected that patients understand their condition, and the recommended treatment’s benefits, harms, and alternatives.1 However,
patients often make decisions regarding complex
medications with incomplete knowledge2 and may
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for them to provide patients with a medication decision guide created by a pharmaceutical company in
accordance with Food and Drug Administration
(FDA) guidelines. These pharmaceutical industry
decision guides (Pharm Booklet) are a form of directto-consumer communication that are required by the
FDA to provide a balanced presentation of the risks
and benefits. Medication guides only describe the
drug’s indication for usage, not the specific benefits,
and present side effects in long lists, which may not
distinguish between clinically important and unimportant side effects.7 They have been criticized for
not providing data on how well a drug works, leading consumers to over-estimate disease risk, treatment benefits, and side effects.7-9 The full effects of
this information architecture are not fully known but
could include biased appraisals of drug benefits and
risks, reduced participation in decision making (i.e.,
accepting the default physician recommendations),
and increased decisional conflict about the use of
effective therapies.9-11
Patient decision aids (PtDA) are an alternative
approach to make information accessible, increase
patient understanding of complex risk information,
and facilitate patient participation, which can lead
to more value-concordant medication decisions.
The International Patient Decision Aids Standards
Collaboration (IPDAS) promulgates a set of criteria
for a good PtDA.12 Despite recognition that PtDA
could broadly improve healthcare, their adoption
has been slow due to cultural, professional, and regulatory barriers.7,13,14 The purpose of this study is to
Received 15 February 2014 from Department of Medicine,
Rheumatology, Michigan State University, College of Human Medicine
Grand Rapids, Grand Rapids, MI, USA (RWM, ATE, JDB, AJH);
Michigan State University College of Human Medicine, Grand Rapids,
Grand Rapids, MI, USA (RDE); Department of Psychology, Calvin
College, Grand Rapids, MI, USA (DJT). The investigators funded this
work, which ensured the authors’ independence in designing the
study, interpreting the data, writing, and publishing the report. They
have no financial interest in any form that could create a potential conflict of interest or the appearance of conflict of interest with regard to
this work. The Enbrel Decision Guide booklets were provided, for the
study, at no cost, by Amgen. Amgen was not involved in patient
selection, data collection, data analysis or writing of the manuscript.
Revision accepted for publication 19 December 2016.
Supplementary Material for this article is available on the Medical
Decision Making Web site at http://journals.sagepub.com/home/mdm.
Address correspondence to Richard W. Martin, Department of
Medicine, Rheumatology, Michigan State University, College of
Human Medicine Grand Rapids, Grand Rapids, MI 49546, USA;
e-mail: martin@mi-arthritis.com.

578  MEDICAL DECISION MAKING/JULY 2017

directly compare the effects of a Pharm Booklet with
IPDAS-compliant PtDAs15 on decision making.
METHODS
Design and Setting
We conducted a single-blind, randomized controlled study of 3 educational interventions to support RA patients who had not previously taken a
biologic DMARD, in making a simulated decision
about intensifying medical therapy by adding etanercept to their current regimen (see Figure 1). The
Michigan State University Institutional Review
Board determined that the research protocol was
exempt from review. The study population was
men and women with RA16 treated in a community
rheumatology practice. The sample frame was created from the practice electronic health record registry (EHR). All subjects received care between July
24, 2012 and July 23, 2013, and were billed under
the ICD-9 code 714.0 (RA). From the records, 1,637
adult patients were identified. All patients were
considered for inclusion in the study. Inclusion criteria were assured by electronic search and manual
review of the EHR, to confirm both the diagnosis of
RA and that there was no past use of biologic
DMARDs. Of the patients identified, 797 biologic
DMARD-naı̈ve RA patients were selected and
included in a 3-contact mail survey using the methods
described by Dillman.17 Mailings and cover letters
were addressed from each patient’s rheumatologist.
The first question of the survey instrument inquired if
the patient had RA and if they had previously taken a
TNF blocking DMARD, like etanercept. In accordance
with the research provision of the practice HIPAA
statement, patient records were reviewed and the most
recent summary scores of the Health Assessment
Questionnaire 2 (HAQ2)18 and Clinical Disease
Activity Index (CDAI)19 were extracted and written on
the last page of the questionnaire. Although the questionnaire was anonymous, demographic characteristics
of the survey sample were recorded in a separate database to permit comparison of the demographics of
responders and non-responders.
Decision Support Interventions
LONG DA
We previously developed a prototype patient
decision aid for patients considering initiating the
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Figure 1 Study Design.

synthetic
DMARD methotrexate to treat their RA.4,
20, 21
The decision aid followed the steps involved
in the Ottawa Decision Support framework 22 and
adhered to the design specifications of the IPDAS.15
This produced a 24-page, 21.5 cm 3 14 cm (8.5- 3
5.5-inch) booklet. Pre-testing demonstrated this
was acceptable to RA patients and significantly
increased relevant knowledge. Appraisal with the
IPDAS instrument disclosed a quality score of 74 (0
to 100), which is in the range of existing benchmark
decision aids.20 We adapted the content of this
methotrexate PtDA to be appropriate for patients
considering initiating etanercept to treat their RA.
For example, information was added on the potential adverse events from etanercept, which are not
encountered with methotrexate therapy: injection
site reactions, risk of reactivation of tuberculosis or
other latent infections, and induction of immunological reactions. Sections elaborating the risks of
methotrexate liver and lung toxicity were deleted.
The LONG DA was 24 pages and contained the
decision/choice set, and the following information:
RA and Its Treatments, Information on Enbrel,
Chance of Improving RA, Slowing Joint Damage,
Chance of Serious Infection and Other Possible
Harms, a Summary of Possible Benefits and Harms.
It also included a decision matrix, a values clarification rating table, and a brief reflection on decision
quality (see Appendix)..
SHORT DA
We developed a 2-page SHORT DA based on the
LONG DA. The first page presented the decision/
choice set, brief information on Enbrel, visual representations of the sections on Chance of Improving
RA, Slowing Joint Damage, Chance of Serious
Infection and Other Possible Harms. The second
page contained a Summary of Possible Benefits and
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Harms, a decision matrix, a values clarification
table, and brief self-reflection on decision quality
(see Appendix).
Pharm Booklet
The third decision support was a 35-page, 23 cm 3
10 cm (9.0- 3 4.0-inch) Amgen Enbrel Treatment
Guide pharmaceutical material. This provided qualitative information on efficacy, safety, and administration procedures. Distributed through the medication information, there were 6 photos of RA patients
linked to a brief, personal testimonial about their
use of etanercept. In addition, the Enbrel Treatment
Guide contained the FDA-mandated Prescribing
Information, Medication Guide and Instructions for
Use, which were folded in a back-cover pocket.
When unfolded, the Prescribing Information and
Medication Guide were a 2-sided, 76 cm 3 53 cm
(30- 3 21-inch) leaflet. The complete content is available online.23
Decision Scenario
In the hypothetical decision, patients were
instructed to:
‘‘Imagine that your RA has become more active
than you want to tolerate. You approached your
doctor about switching to a new disease-modifying
drug. Your rheumatologist suggested adding Enbrel
to your current regimen of medication. He has given
you a treatment guide to read and asked you to call
him tomorrow with your decision about whether or
not you would like to start it.’’
The patient was then instructed to open the
sealed ‘‘medication information envelope’’ and to
pause and read the enclosed ‘‘Treatment Guide’’.
Below the instructions, there was an image of the
decision support to which the patient was
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randomized (see Appendix). Patients allocated to
receive the Pharm Booklet, were shown a picture of
the location of the ‘‘Medication Guide’’. They were
instructed, ‘‘Be sure to pull out and read the
‘Medication Guide’ tucked in the back pocket of the
booklet, too.’’ This was followed by the instructions; ‘‘When you have finished reviewing the materials, please place them back in the envelope until
you finish the questionnaire.’’
On the next page, they were asked, ‘‘If you had to
decide today, what would your decision be?’’ and
choose between ‘‘I would call to request a prescription to start Enbrel now’’ or ‘‘I would choose not to
start Enbrel now.’’ Patients were then instructed to
turn the page and finish the questionnaire without
looking back at the decision support materials.
Study Measurements
The survey instrument assessed the following
patient variables:
Demographics
Age, sex, ethnicity, education, and household
income were elicited. Participants who reported
having less than a high-school graduation were classified as having low education. Participants who
reported Hispanic, African, or Native American ethnicity were classified as having minority status.
Low income was defined as total household income
\$25,000, which is 106% the 2013 Federal Poverty
Level for a family of 4.24
RA- and DMARD-related Experience
RA disease duration, past, and current DMARD
usage was elicited. We assessed the level of current
(traditional) DMARD-related side effects with the
item, ‘‘Think about the RA disease modifying drug
you most recently started. Are you having any side
effects from it that bother you now?’’.2
RA Disease Status
The HAQ2,15 a validated measure of functional
impairment, was utilized as an indicator of RA
severity. The Clinical Disease Activity Index (CDAI)
is a single, continuous, composite measure of RA
disease activity that ranges from 0 to 76.16 A score
of 0 to 10 is classified as low, 11 to 22 as moderate,
and 23 as high disease activity.
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Decisional Conflict
We used O’Connor’s 16-item statement format of
the Decisional Conflict Scale (DCS)25 to evaluate the
quality of the decision made about etanercept. This
has 4 subscales: Informed, Values Clarity, Support,
and Effective Decision. When combined, this yields a
standardized score in the range of 0 to 100. The DCS
can discriminate between groups who make and defer
decisions, with an effect size of 0.4 or more. DCS
scores of less than 25 are associated with implementing decisions, and scores greater than 37.5 are associated with uncertainty or delaying a decision.26
Etanercept-related Knowledge
We created a test of patient knowledge that
would be relevant to a patient considering intensifying their RA therapy by adding etanercept to their
current treatment regimen. We began by comparing
the content of 5 instruments previously reported for
assessing patient knowledge in RA.20, 27-30 Within
this pool of test items, we identified 37 relevant
educational domains. From this, we generated 12
single-answer, multiple-choice knowledge test
items. Using the Enbrel package insert and medication guide as our primary reference document, we
modified these items to cover content relevant to
etanercept (see Appendix): the RA disease process
and consequences of untreated RA (2 items), basic
information about etanercept therapy (2 items), the
potential benefits (2 items) and harms of etanercept
(6 items). Two investigators independently crosschecked the 3-decision support interventions to
ensure that the content of the test items was representative of the educational domains and that the
content needed to correctly answer all questions
was present in all 3-decision support interventions.
Items were modified as needed to meet this requirement. The usability of the test items was evaluated
by 4 rheumatologists and 4 allied health professionals and revised. The same items were used in the
pre-test and post-test, differing only in the arbitrary
re-ordering of the multiple-choice foils in the posttest. Results are reported as the proportion of correctly answered items (possible range, 0.00 to 1.00).
Patient Beliefs about Etanercept
To evaluate patient beliefs about taking etanercept from the perspective of the Integrated Model of
Behavioral Prediction (IMBP),31 we developed 5point Likert scale questions, as follows:
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Beliefs about outcomes of therapy. Three questions probed the patients’ beliefs about the likely
consequences of taking etanercept. ‘If I take Enbrel,
it will improve my pain and stiffness enough to
make a difference in my life’ (anchors: strongly disagree, strongly agree). ‘If I take Enbrel, it will slow
the progression of the RA joint damage’ (anchors:
strongly disagree, strongly agree) ‘If I take Enbrel,
how likely would it be that I would have a serious
side effect in the next year’ (anchors: no risk, absolutely certain I would have a serious side effect).
Normative beliefs. Patients’ normative beliefs
about Enbrel were assessed by asking about their
perception of the beliefs of other people who are
important to them, and how likely they would be
to take etanercept. ‘Most people, like me, who
have active RA despite taking a DMARD like methotrexate, would choose to try Enbrel’ (anchors:
unlikely, very likely).
Perceived behavioral control. Patients’ perceived
ability to successfully act on their decision, which
is an indicator of self-efficacy, was assessed with
one item. ‘I’m confident I could do all that would
be needed to take and monitor Enbrel’ (anchors:
not at all confident, totally confident).
Intention to Take Etanercept
The integrative model of behavioral prediction
proposes that people act on their intentions when
environmental factors do not interfere.31 We measured patients’ intention to take etanercept with the
Likert item: ‘What is the likelihood that you would
consider taking Enbrel today.’ (0 = would never
take, and 9 = absolutely would take).
Formative Evaluation of Interventions
We used three 5-point Likert scale questions to
compare patients’ perceptions of the acceptability,
effectiveness, and efficiency of each of the interventions as a decision support.32 ‘The materials had the
information I needed to make a decision.’ ‘The
materials were helpful in preparing me to make a
decision about Enbrel.’ ‘The materials were well
organized, easy to read, and contained the right
amount of information.’
Analysis
Descriptive analyses were performed to provide
information on the characteristics of the respondents. Bivariate relationships were evaluated with

ORIGINAL ARTICLE

Pearson correlation coefficients, independent samples t tests, and Chi-squared tests, as appropriate.
The effect of the 3-decision support interventions
on continuous patient outcomes was evaluated
with a one-way analysis of variance of variance
(ANOVA) or 2-way repeated ANOVA, as appropriate. Multivariate predictive models of the decision to
intensify care by initiating etanercept were created
with binomial logistic regression.33 Continuous independent variables were mean-centered. Finally, we
evaluated the causal hypothesis that patients’ beliefs
about the outcomes of therapy and normative beliefs
mediate the effects of decision support on choice to
intensify therapy using methods described by Baron
and Kenny.34 All analyses were performed with IBM
SPSS Statistics version 21.0.35
RESULTS
We surveyed 797 patients with RA. All participants were randomized and allocated to an intervention. Subjects were blinded to the allocation.
Data were analyzed for 402 respondents. In addition
to 387 non-respondents, 4 patients had died and 4
had changed address and could not be reached. The
overall response rate was 52.0%. Data from all study
completers were included in the analysis. In the
completed sample, all patients had RA. See Consort
Diagram (Appendix).
Patient Characteristics
We compared the demographic and RA-related
disease characteristics between the overall sample
and the respondents. The overall sample was similar in age (mean, 63.7 y), sex (69% female), ethnicity
(7.5% minority), HAQ2 disability (0.818) and CDAI
(10.8). The proportion of the sample randomized to
each intervention and the completed sample varied
by less than 2% in response rates across groups.
A description of the respondents is presented in
Table 1.
Decision to Intensify Therapy
We found that 31.3% of patients randomized to
receive decisional support from the Pharm Booklet,
chose to intensify therapy by adding etanercept to
their current regimen, as compared with 14.6% of
LONG DA and 14.0% of SHORT DA (x2 (2,394) =
15.68; P \ 0.001).
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Table 1

Patient Characteristics

Pharm Booklet (n = 127)

LONG DA (n = 127)

SHORT DA (n = 145)

64.15 (12.79)
64.3%
6.2%
6.4%
18.0%
10.47 (10.59)
1.68 (.88)
51.42 (17.12)
10.66 (10.09)
0.81 (0.66)

64.92 (11.58)
70.0%
5.5%
1.2%
17.5%
10.34 (8.98)
1.68 (.94)
52.03 (15.81)
10.23 (9.54)
0.76 (0.66)

64.2 (12.73)
65.8%
6.8%
10.6%
14.9%
10.48 (10.03)
1.59 (.87)
50.34 (18.80)
10.08 (9.26)
0.70 (0.62)

Age (y)
Female Sex
Minority
Low Education
Low Income
RA Duration (y)
Current bother from DMARD side effects
Etanercept related knowledge (Baseline)
CDAI Disease Activity
HAQ Disability

P

P
P
P
P
P
P
P
P
P
P

=
=
=
=
=
=
=
=
=
=

0.855
0.504
0.901
0.012a
0.050a
0.979
0.589
0.706
0.887
0.365

a

Significant difference (P \ 0.05).
Data are the mean (SD).

Formative Evaluation of Decision Support
Interventions
Patients rated perceived acceptability, effectiveness, and efficiency of each of the interventions
above the mean on each of the 5-point Likert rating
scales; there was no statistically significant difference in mean ratings among interventions.
Etanercept Related Knowledge
Test Reliability and Validity
The mean item difficulty for the pre-test was .51
(range, 0.08 to 0.89) and post-test .61 (range 0.20 to
0.88). Reliability of the combined index was adequate with a Cronbach a = 0.70. The item-total
index correlations ranged from 0.28 to 0.46. Posttest knowledge correlated negatively with decisional conflict (r = -0.139, P \ 0.02) suggesting modest
construct validity.
Effect of Intervention
Results of pre- and post-intervention etanercept
related knowledge tests are summarized in Figure 2.
We evaluated change in pre-test to post-test etanercept knowledge as a function of intervention by utilizing a 2-way, mixed model ANOVA, with time
(pretest and posttest) as the within-subjects variable, and intervention (Pharm Booklet group, LONG
DA group, and SHORT DA group) as the betweensubjects variable. The main effects were found for
time (F (1,399) =125.454; P \ 0.001), and intervention (F (2,399) = 3.209; P = 0.016). This significant
interaction was further explored with follow-up
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Figure 2 Change in etanercept related knowledge with decision
support.

one-way ANOVAs and post-hoc t tests. First, a oneway ANOVA on pre-test etanercept knowledge
showed that, as expected, for each level of intervention, these groups did not significantly differ (F
(2,399) = 0.335, P = 0.715; 51.429 [17.127] for
Pharm Booklet group; 52.034 [15.808] for LONG DA
group; 50.343 [18.797] for SHORT DA group). Next,
a one-way ANOVA was conducted to determine
whether the level of intervention influenced the
post-test etanercept knowledge means. This effect
was significant (F (2,399) = 9.809; P \ 0.001). Tukey
HSD post-hoc t tests indicated that the mean posttest knowledge for the Pharm Booklet group (54.849
[18.712]) was significantly lower than that for both
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Table 2

Belief Improve Symptoms
Belief Slow Progression
Belief Have Adverse Event
Belief Social Norm
Belief Self-efficacy
Decisional Conflict

Beliefs about Etanercept

Pharm Booklet (n = 127)

LONG DA (n = 127)

SHORT DA (n = 145)

3.28 (1.13)
3.61 (1.07)
3.23 (.95)
3.04 (1.04)
3.48 (1.37)
28.61 (15.64)

3.16 (1.13)
3.56 (.95)
3.25 (.86)
2.79 (1.13)
3.43 (1.40)
27.13 (16.28)

2.85 (1.04)
3.37 (1.01)
3.25 (.91)
2.58 (1.08)
3.20 (1.34)
29.15 (15.23)

P

P
P
P
P
P
P

=
=
=
=
=
=

0.050a
0.134
0.984
0.003a
0.174
0.575

a

Significant difference (P . 0.05).

the LONG DA (62.530 [18.889]) and SHORT DA
(65.811 [23.340]) groups, with no significant difference between the LONG DA and SHORT DA groups.
All interventions resulted in an increase in etanercept knowledge but the LONG DA and SHORT
DA materials were significantly more effective in
increasing knowledge than the Pharm Booklet.
Beliefs about Etanercept
The results of the post-intervention testing of
patient beliefs about etanercept are summarized in
Table 2. We explored differences in patients’ beliefs
about the outcomes of intensifying therapy with etanercept as a function of the intervention groups
through a series of one-way ANOVA tests. First, the
effect of the intervention group on belief about outcome of therapy was significant (F (2,387) = 5.454,
P = 0.005). Tukey HSD post-hoc analyses revealed
that the Pharm Booklet group (3.28 [1.125]) had a
significantly higher belief that etanercept would
improve RA symptoms than did the SHORT DA
group (2.85 [1.039]), whereas the LONG DA group
(3.16 [1.125]) did not significantly differ from the
others. Second, the effect of the intervention on normative beliefs was also significant (F (2, 386) =
5.926; P = 0.003). Tukey HSD post-hoc analyses
revealed a pattern of differences similar to that
found for beliefs about outcome of therapy: the
Pharm Booklet group (3.04 [1.042]) had a significantly higher belief that other patients with RA in a
similar situation would take etanercept than did
those in the SHORT DA group (2.58 [1.76]), while
the LONG DA group (2.79 [1.125]) did not significantly differ from the others. Finally, no differences
were found among the intervention groups for patient
beliefs about how much etanercept would slow RA
disease progression (F (2, 388) = 2.020; P = 0.134), for
belief that etanercept would cause a serious adverse
event in the next year (F (2, 388) = 0.017; P = 0.984),
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and for patients’ self-efficacy to take the new medication (F (2, 388) = 1.756; P = 0.174).
Decisional Conflict
Decisional conflict was assessed immediately
after patients were asked to make a choice regarding
intensifying therapy. The mean overall DCS score
was 28.45 (15.79) with a range of 0 to 100. We evaluated the mean overall DCS score and DCS subscale
scores by decision support intervention with one-way
ANOVA and found no significant differences. We
also found no significant differences in the proportion
of patients with DCS scores .37.5 or DCS scores
\25.0 (x2(2) = 3.06, P = 0.22; x2(2) = 0.483, P = 0.79).
Predictors of Decision to Intensify Therapy
We developed a preliminary logistic regression
model to describe the relationships among patient
characteristics, decision support intervention, and
choice to intensify therapy. Dummy variables were
created for Pharm Booklet and SHORT DA to allow
the covariates to be included in the logistic equation. We used purposeful selection of covariates,
including all potentially clinically relevant variables, to control for confounding.36 In the first step,
we created univariate logistic regression models for
18 potential predictor variables. Eleven variables
were not predictive (P  0.25) and were excluded:
female gender, low income, minority status, bother
by side effects from current anti-rheumatics, RA disease activity (CDAI), functional disability (HAQ2),
etanercept related knowledge, patients’ beliefs
about how etanercept would slow RA disease
progression, patients’ self-efficacy to take the new
medication, values clarity, and overall decisional
conflict.
Following this, we created a multivariate model
by entering the 7 remaining variables, into a
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Table 3

Logistic Regression: Predictors of Decision to Intensify Therapy
95%CI for Odds Ratio

Intervention: Pharm Booklet
Intervention: SHORT DA
Belief: Have Serious Side Effect
Belief: Improve Symptoms
Belief: Social Norm
Age
Low Education
Constant

Odds Ratio

Lower

Upper

2.35
1.48
0.59
2.55
2.24
0.97
0.39
0.46

1.25
0.64
0.39
1.71
1.49
0.95
0.12

4.41
3.44
0.89
3.80
3.35
0.99
1.31

backward, stepwise logistic regression. We opted to
retain low education in the final model regardless
of its association as an important control variable.
The final model fit was excellent in predicting treatment choice in 83.6% of cases, with the Nagelkerke
R2 explaining 44.2% of variation. The Hosmer
and Lemeshow Test P value was high (P \ 0.752),
indicating all systematic variance has been accounted
for in the model. The Hosmer and Lemeshow
Contingency Test showed close agreement between
the expected and observed frequencies of the model
across deciles in classifying patients into choice
groups. Tolerances were .0.2, suggesting the absence
of significant multicollinearity of covariates. We also
evaluated inclusion of the 2-way interactions among
age, low education, and the Pharm Booklet and
SHORT DA dummy variables, but no interaction
terms contributed significantly to the model, and we
retained only the main effects.
The results are summarized in Table 3. The odds
ratios of covariates predicting choice to intensify
therapy were: Belief: Improve Symptoms, 2.55,
95%CI = 1.71 to 3.80; Intervention: Pharm Booklet
decision support 2.35, 95%CI = 1.25 to 4.41; Belief Social Norm 2.24 95%CI = 1.49 to 3.35; Belief: Have
Serious Side Effect, 0.59, 95%CI = 0.39 to 0.89; and
Age, 0.97, 95%CI = 0.95 to 0.99. The regression
coefficients for low educational level and SHORT
DA were not significant.
Mediation Analysis
We next performed a mediational analysis to
examine whether the decision support intervention’s effect on the intention to take etanercept was
mediated by patient beliefs about etanercept. As
can be seen in Figure 3, the decision support
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intervention had a significant relationship with the
intention to take etanercept (0 to 9 scale), such that
patients given the Pharm Booklet indicated a higher
intention of taking the drug than those given the
Decision Aid. The intention to take etanercept was
strongly related to the decision to take etanercept in
a single factor logistic regression model (R2 =
0.582). In terms of patient beliefs, the decision support intervention only had a significant effect on the
belief that symptoms would improve and the normative beliefs about etanercept, so only these were
used as mediators. The Pharm Booklet group was
more likely to believe that their symptoms would
improve and that most people like themselves
would choose to take etanercept compared to the
Decision Aid group. Increases in both patient beliefs
were then associated with increases in the patients
expressed intentions of taking etanercept. Once we
accounted for the mediators, the direct effect of the
decision support intervention was no longer significant. Furthermore, the indirect effect of decision
support intervention was significant through both
mediators. Taken together, this suggests the effect of
the decision intervention on patients’ intention to
take etanercept was mediated by patients’ beliefs
about the medication.
DISCUSSION
Patients may face complex decisions when they
consider a proposal to intensify medical therapy. To
make an informed choice, patients should have
accurate beliefs about the safety and efficacy of a
proposed therapy. There is a renewed debate
regarding the ethics of the content in direct-toconsumer pharmaceutical advertising,37 which is
relevant to pharmaceutical company ‘‘patient
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decision guides’’ distributed by industry representatives to physicians. The basis of the argument is
that patients must be able to make decisions that are
consistent with their personal values and that they
are formed by a reliable method.38 However, in
addition to providing information, pharmaceutical
advertisements construct persuasive messages
aimed to induce a positive attitude about their product by pairing it to another object to which the
patient already has a positive attitude.39 The psychological term for this is evaluative conditioning.
The product can be paired with: an image which
evokes a hopeful, positive mood,38 a celebrity testimonial,40 or by describing a norm of how most people who choose in this situation (Social Norm); i.e.,
with a salient patient testimonial.40
All 3 of these approaches are utilized in the
Pharm Booklet used in our study. There are images
of African-American, Hispanic and Caucasian
adults participating in physical activities in beautiful outdoor settings making statements that include
words like: ‘‘good’’, ‘‘tremendous’’, ‘‘manageable’’,
‘‘well’’, ‘‘healthier’’, ‘‘relief’’, and ‘‘active lifestyle’’.
In addition, there is a testimonial from the popular
‘‘Hall of Fame’’ golfer Phil Mickelson, who takes
etanercept for psoriatic arthritis.
Overall, it is unknown how strong the effects of
any of these methods of evaluative conditioning are
on the formation of beliefs about medications and
patients’ responses to a physician’s recommendation to intensify therapy.38 An ethical conflict arises
if the Pharm Booklet produces positive beliefs about
drug safety and efficacy that are not fully accurate,
yet shape the patient’s choice toward adopting the
new therapy. In this case, the persuasive materials
undermine patient autonomy, as the medication
decision might be based on an emotional response
rather than an appraisal of the facts about efficacy
and safety.38
Our study attempts to begin to unravel the question of what effects evaluative conditioning could
have by comparing the Pharm Booklet to decision
aids. PtDA are purposefully designed without
using persuasive strategies, presenting benefits
and harms neutrally, often supporting numerical
information with visual aids to reduce the cognitive load and aid in42the accurate understanding of
the probabilities.41,
Exposure to the Pharm Booklet doubled the rate
of patient choice to intensify therapy (increased
absolute rate of adoption by 17%) as compared with
the SHORT DA and the LONG DA. We demonstrated that both DAs produced a greater increase in
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Figure 3 Mediational model of the intervention on patient intentions. Total indirect effect: b = 0.094*. Indirect effect through
‘‘Belief Improve RA Symptoms’’: b = 0.050*. Indirect effect
through ‘‘Perceived Social Norms’’: b = 0.044. * Indicates P \
0.05. Indicators of significance for the indirect effects were
obtained using 5,000 bootstrap resamples.

relevant knowledge but that the greater knowledge
and feeling of being informed did not have an
impact on the patient’s beliefs about medication,
decisional conflict, or their choice to intensify
therapy.
The Integrative Model of Behavioral Prediction
proposes that intention and ultimate adoption of a
new therapy can be predicted by 3 types of beliefs:
1) expected outcomes of therapy, 2) social norms,
and 3) self-efficacy to act on the intention.31 In
Figure 4, we conceptualize how patient characteristics, decisional support, and potential mediating
medication beliefs could influence decisional outcomes. In the current study, predictive models
demonstrate a stronger relationship between beliefs
about outcomes of therapy and social norms on
decisional outcomes than patient characteristics. In
addition, it appears the mechanisms of the Pharm
Booklet’s effects are partially mediated through persuasive communication techniques that influence
patients’ belief symptoms: This will improve and
increase social normative beliefs rather than by
increase relevant knowledge, clarifying patient values about positive or negative treatment outcomes,
or increasing their self-efficacy.
Our study has several limitations. First, it was a
simulated decision rather than a high-stakes, realtime clinical decision. In addition, it was conducted
as a mail survey; thus, we cannot be sure how much
time or effort patients expended in reviewing the
decisional support materials. We expected some
variation amongst patients, as the incomplete utilization of decision aids by patients has been
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Figure 4 Simplified model of the effects of decisional support on the choice to intensify therapy.

previously reported and may relate to the salience
of materials to the individual patient.43,44 Another
uncertainty is the effect of the design of the decision/choice set in the PtDAs. The choice architecture of the LONG and SHORT DA directed the
patient to consider 5 choices: take no treatment,
continue current treatment, begin Enbrel now, ask
doctor about other options, and defer choice for
now. This reflects real-world conditions, where
PtDA are often used as an adjunct to the medical
office visit. It frames the decision as more than,
‘‘should I take or reject the proposed therapy now’’
to a broader starting point of ‘‘do I want to take any
treatment for RA’’ and removes limits to the time of
deliberation while considering ‘‘do I need other
information or to consider additional options’’.
Because our simulated decision was an experiment,
we forced subjects to make a choice ‘‘to call to
request a prescription to start Enbrel now’’ or
‘‘choose not to start Enbrel now’’. For this reason,
our results may not fully reveal how decision support performs in the field. However, in some ways
this may mimic real ambulatory practice where a
physician introduces treatment options and send
the patient home with support materials to reflect
on their preferences and choose. Alternatively, by
choice bracketing—i.e., reducing from a 5-choice set
to 2 choices: 1. start Enbrel now v. 2. choose not to
start Enbrel now (no treatment, continue current treatment, ask about other options, defer choice for
now)—it is possible that we could have introduced a
broad bracketing effect.45 This could potentially result
in different patient choices than in a clinical setting,
where all 5 choice options are available. The direction
and magnitude of this effect is context specific and
could not be predicted with the current study design.
Given the respondent burden to read educational
materials and complete a pre- and post-survey, we
felt the response rate was excellent at 52%. We
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compared the demographics of the original sample
frame with the completed sample and found them to
be similar. When compared to a random sample of
patients seen in Michigan community rheumatology
practices, our completed sample contained a lower
proportion of low-education patients (6.2% v.
14.2%) but a similar minority representation (6.3%
v. 7.3%).2 Together, these suggest that the results can
be reasonably generalized to other community rheumatology practice populations, though additional
study is needed in low education populations.
In conclusion, this study has several implications
for practice and policy. Schwartz and Woloshin of
the Dartmouth Center for Health Policy and Practice
have lobbied the FDA and legislators to revise their
policies to mandate providing medication efficacy
data and create new standards for presenting side9
effect data in non-biased formats to patients.8,
Unfortunately, the FDA deferred action for an undisclosed 3- to 5-y study period.7 The results of our
study provide further evidence that the choice architecture in the Pharm Booklet contained powerful,
persuasive content that may lead patients to develop
inaccurate beliefs about the efficacy or safety of the
treatment, and it undermines their decision making
autonomy. From a societal viewpoint, these Pharm
Booklets could lead to the overutilization of recommended medications by nudging patients toward
adopting proposed commercial products without a
critical consideration of the drug attributes. PtDA
offer a balanced alternative that clinicians could use
to structure complex medication discussions and
support more informed patient choices. We believe
patients would benefit from their use.
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